Crystalys Therapeutics emerges from stealth with $205M Series A to advance late-stage gout therapy

San Diego, CA, September 30, 2025 (Reuters) -- Crystalys Therapeutics announced its launch from stealth with a $205 million Series A round co-led by Novo Holdings, SR One, and Catalys Pacific to fund late-stage global trials of its gout drug, dotinurad. The oral once-daily therapy targets URAT1 to reduce uric acid buildup and is being tested as a second-line treatment for patients unresponsive to current options. CEO James Mackay said the FDA approved two distinct late-stage trial designs, aiming to address both gout flares and tophi resolution.

Read full article here.